- Home
- AIM vs PEV Comparison
AIM vs PEV Comparison
Compare AIM & PEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- PEV
- Stock Information
- Founded
- AIM 1966
- PEV 2002
- Country
- AIM United States
- PEV United States
- Employees
- AIM N/A
- PEV N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- PEV Auto Manufacturing
- Sector
- AIM Health Care
- PEV Consumer Discretionary
- Exchange
- AIM Nasdaq
- PEV Nasdaq
- Market Cap
- AIM 9.8M
- PEV 10.9M
- IPO Year
- AIM N/A
- PEV 2022
- Fundamental
- Price
- AIM $0.14
- PEV $0.33
- Analyst Decision
- AIM Strong Buy
- PEV
- Analyst Count
- AIM 2
- PEV 0
- Target Price
- AIM $2.75
- PEV N/A
- AVG Volume (30 Days)
- AIM 1.5M
- PEV 15.4M
- Earning Date
- AIM 04-01-2025
- PEV 02-12-2025
- Dividend Yield
- AIM N/A
- PEV N/A
- EPS Growth
- AIM N/A
- PEV N/A
- EPS
- AIM N/A
- PEV 0.06
- Revenue
- AIM $190,000.00
- PEV $26,119,000.00
- Revenue This Year
- AIM N/A
- PEV N/A
- Revenue Next Year
- AIM $1,693.10
- PEV N/A
- P/E Ratio
- AIM N/A
- PEV $5.94
- Revenue Growth
- AIM N/A
- PEV 424.69
- 52 Week Low
- AIM $0.12
- PEV $0.20
- 52 Week High
- AIM $0.62
- PEV $1.39
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- PEV 53.12
- Support Level
- AIM $0.12
- PEV $0.25
- Resistance Level
- AIM $0.21
- PEV $0.38
- Average True Range (ATR)
- AIM 0.02
- PEV 0.05
- MACD
- AIM -0.00
- PEV 0.01
- Stochastic Oscillator
- AIM 22.88
- PEV 23.95
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About PEV Phoenix Motor Inc.
Phoenix Motor Inc is an electrification solutions provider for the commercial vehicle industry as well as other industries. It designs, develops, manufactures, assembles, and integrates electric drive systems and light and medium-duty electric vehicles (EVs) and markets and sells electric vehicle chargers for the commercial and residential markets. The company operates two primary brands, Phoenix Motorcars, which focuses on commercial products including medium-duty electric vehicles, chargers, and electric forklifts, and EdisonFuture which intends to offer light-duty electric vehicles.